STANFORD UNIVERSITY

Nomic and PICI collaborate to profile ~3000 blood samples from RADIOHEAD study using nELISA™ to understand immunotherapy responses, aiming to improve patient care through precision medicine.

OncLive On Air podcast discusses FDA approval of afamitresgene autoleucel (afami-cel) for advanced synovial sarcoma, supported by Adaptimmune Therapeutics. Dr. Allison Betof Warner, Stanford University, highlights SPEARHEAD-1 trial results and multidisciplinary collaboration in cell therapy administration.

Stanford and Rensselaer Polytechnic researchers developed an AI model improving clinical trial approval predictions, integrating selective classification with Hierarchical Interaction Network (HINT) to quantify uncertainty, achieving significant accuracy improvements in Phase I, II, and III trials.

Health in Harmony's program in Borneo has reduced deforestation by 70% over 10 years by offering farmers $200 for chainsaws and $450 for sustainable businesses. The initiative also includes a medical center reducing infant mortality by 67%, and innovative healthcare payment solutions. Since 2017, 279 loggers have turned in their chainsaws, protecting over 100,000 trees.

The TRIPOD+AI update provides harmonised guidance for reporting prediction model studies, superseding TRIPOD 2015, to accommodate AI and machine learning methods. The new 27-item checklist aims for complete, accurate, and transparent reporting, facilitating study appraisal and model implementation.

GLP-1 drugs like Ozempic and Wegovy may prevent up to 34,000 heart attacks and strokes annually, potentially serving as primary prevention for patients with mild or moderate CVD.

Despite numerous treatment options for metastatic castration-resistant prostate cancer (mCRPC), cross-resistance and early-line use of androgen receptor–pathway inhibitors (ARPIs) limit options. Ongoing research focuses on novel agents like AR degraders to address unmet needs. Radioligand therapy and clinical trials are crucial for advancing care, with PSMA imaging and genomic testing reshaping treatment paradigms.

New research from Stanford University suggests yoga and other exercises can reduce urinary incontinence episodes by 65% in women, similar to medication effectiveness. The 12-week study involved 240 women, with half practicing yoga and the other half engaging in general exercise, both seeing significant reductions in incontinence episodes.

Sandy Srinivas discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for PSMA-positive mCRPC, highlighting its favorable tolerability, convenient schedule, and suitability for older patients. The drug's AE profile is milder than chemotherapy, and the VISION trial showed high eligibility for treatment, with ongoing evaluation refining its use.